[{"path":"https://avi-kenny.github.io/vaccine/LICENSE.html","id":null,"dir":"","previous_headings":"","what":"GNU General Public License","title":"GNU General Public License","text":"Version 3, 29 June 2007Copyright © 2007 Free Software Foundation, Inc. <http://fsf.org/> Everyone permitted copy distribute verbatim copies license document, changing allowed.","code":""},{"path":"https://avi-kenny.github.io/vaccine/LICENSE.html","id":"preamble","dir":"","previous_headings":"","what":"Preamble","title":"GNU General Public License","text":"GNU General Public License free, copyleft license software kinds works. licenses software practical works designed take away freedom share change works. contrast, GNU General Public License intended guarantee freedom share change versions program–make sure remains free software users. , Free Software Foundation, use GNU General Public License software; applies also work released way authors. can apply programs, . speak free software, referring freedom, price. General Public Licenses designed make sure freedom distribute copies free software (charge wish), receive source code can get want , can change software use pieces new free programs, know can things. protect rights, need prevent others denying rights asking surrender rights. Therefore, certain responsibilities distribute copies software, modify : responsibilities respect freedom others. example, distribute copies program, whether gratis fee, must pass recipients freedoms received. must make sure , , receive can get source code. must show terms know rights. Developers use GNU GPL protect rights two steps: (1) assert copyright software, (2) offer License giving legal permission copy, distribute /modify . developers’ authors’ protection, GPL clearly explains warranty free software. users’ authors’ sake, GPL requires modified versions marked changed, problems attributed erroneously authors previous versions. devices designed deny users access install run modified versions software inside , although manufacturer can . fundamentally incompatible aim protecting users’ freedom change software. systematic pattern abuse occurs area products individuals use, precisely unacceptable. Therefore, designed version GPL prohibit practice products. problems arise substantially domains, stand ready extend provision domains future versions GPL, needed protect freedom users. Finally, every program threatened constantly software patents. States allow patents restrict development use software general-purpose computers, , wish avoid special danger patents applied free program make effectively proprietary. prevent , GPL assures patents used render program non-free. precise terms conditions copying, distribution modification follow.","code":""},{"path":[]},{"path":"https://avi-kenny.github.io/vaccine/LICENSE.html","id":"id_0-definitions","dir":"","previous_headings":"TERMS AND CONDITIONS","what":"0. Definitions","title":"GNU General Public License","text":"“License” refers version 3 GNU General Public License. “Copyright” also means copyright-like laws apply kinds works, semiconductor masks. “Program” refers copyrightable work licensed License. licensee addressed “”. “Licensees” “recipients” may individuals organizations. “modify” work means copy adapt part work fashion requiring copyright permission, making exact copy. resulting work called “modified version” earlier work work “based ” earlier work. “covered work” means either unmodified Program work based Program. “propagate” work means anything , without permission, make directly secondarily liable infringement applicable copyright law, except executing computer modifying private copy. Propagation includes copying, distribution (without modification), making available public, countries activities well. “convey” work means kind propagation enables parties make receive copies. Mere interaction user computer network, transfer copy, conveying. interactive user interface displays “Appropriate Legal Notices” extent includes convenient prominently visible feature (1) displays appropriate copyright notice, (2) tells user warranty work (except extent warranties provided), licensees may convey work License, view copy License. interface presents list user commands options, menu, prominent item list meets criterion.","code":""},{"path":"https://avi-kenny.github.io/vaccine/LICENSE.html","id":"id_1-source-code","dir":"","previous_headings":"TERMS AND CONDITIONS","what":"1. Source Code","title":"GNU General Public License","text":"“source code” work means preferred form work making modifications . “Object code” means non-source form work. “Standard Interface” means interface either official standard defined recognized standards body, , case interfaces specified particular programming language, one widely used among developers working language. “System Libraries” executable work include anything, work whole, () included normal form packaging Major Component, part Major Component, (b) serves enable use work Major Component, implement Standard Interface implementation available public source code form. “Major Component”, context, means major essential component (kernel, window system, ) specific operating system () executable work runs, compiler used produce work, object code interpreter used run . “Corresponding Source” work object code form means source code needed generate, install, (executable work) run object code modify work, including scripts control activities. However, include work’s System Libraries, general-purpose tools generally available free programs used unmodified performing activities part work. example, Corresponding Source includes interface definition files associated source files work, source code shared libraries dynamically linked subprograms work specifically designed require, intimate data communication control flow subprograms parts work. Corresponding Source need include anything users can regenerate automatically parts Corresponding Source. Corresponding Source work source code form work.","code":""},{"path":"https://avi-kenny.github.io/vaccine/LICENSE.html","id":"id_2-basic-permissions","dir":"","previous_headings":"TERMS AND CONDITIONS","what":"2. Basic Permissions","title":"GNU General Public License","text":"rights granted License granted term copyright Program, irrevocable provided stated conditions met. License explicitly affirms unlimited permission run unmodified Program. output running covered work covered License output, given content, constitutes covered work. License acknowledges rights fair use equivalent, provided copyright law. may make, run propagate covered works convey, without conditions long license otherwise remains force. may convey covered works others sole purpose make modifications exclusively , provide facilities running works, provided comply terms License conveying material control copyright. thus making running covered works must exclusively behalf, direction control, terms prohibit making copies copyrighted material outside relationship . Conveying circumstances permitted solely conditions stated . Sublicensing allowed; section 10 makes unnecessary.","code":""},{"path":"https://avi-kenny.github.io/vaccine/LICENSE.html","id":"id_3-protecting-users-legal-rights-from-anti-circumvention-law","dir":"","previous_headings":"TERMS AND CONDITIONS","what":"3. Protecting Users’ Legal Rights From Anti-Circumvention Law","title":"GNU General Public License","text":"covered work shall deemed part effective technological measure applicable law fulfilling obligations article 11 WIPO copyright treaty adopted 20 December 1996, similar laws prohibiting restricting circumvention measures. convey covered work, waive legal power forbid circumvention technological measures extent circumvention effected exercising rights License respect covered work, disclaim intention limit operation modification work means enforcing, work’s users, third parties’ legal rights forbid circumvention technological measures.","code":""},{"path":"https://avi-kenny.github.io/vaccine/LICENSE.html","id":"id_4-conveying-verbatim-copies","dir":"","previous_headings":"TERMS AND CONDITIONS","what":"4. Conveying Verbatim Copies","title":"GNU General Public License","text":"may convey verbatim copies Program’s source code receive , medium, provided conspicuously appropriately publish copy appropriate copyright notice; keep intact notices stating License non-permissive terms added accord section 7 apply code; keep intact notices absence warranty; give recipients copy License along Program. may charge price price copy convey, may offer support warranty protection fee.","code":""},{"path":"https://avi-kenny.github.io/vaccine/LICENSE.html","id":"id_5-conveying-modified-source-versions","dir":"","previous_headings":"TERMS AND CONDITIONS","what":"5. Conveying Modified Source Versions","title":"GNU General Public License","text":"may convey work based Program, modifications produce Program, form source code terms section 4, provided also meet conditions: ) work must carry prominent notices stating modified , giving relevant date. b) work must carry prominent notices stating released License conditions added section 7. requirement modifies requirement section 4 “keep intact notices”. c) must license entire work, whole, License anyone comes possession copy. License therefore apply, along applicable section 7 additional terms, whole work, parts, regardless packaged. License gives permission license work way, invalidate permission separately received . d) work interactive user interfaces, must display Appropriate Legal Notices; however, Program interactive interfaces display Appropriate Legal Notices, work need make . compilation covered work separate independent works, nature extensions covered work, combined form larger program, volume storage distribution medium, called “aggregate” compilation resulting copyright used limit access legal rights compilation’s users beyond individual works permit. Inclusion covered work aggregate cause License apply parts aggregate.","code":""},{"path":"https://avi-kenny.github.io/vaccine/LICENSE.html","id":"id_6-conveying-non-source-forms","dir":"","previous_headings":"TERMS AND CONDITIONS","what":"6. Conveying Non-Source Forms","title":"GNU General Public License","text":"may convey covered work object code form terms sections 4 5, provided also convey machine-readable Corresponding Source terms License, one ways: ) Convey object code , embodied , physical product (including physical distribution medium), accompanied Corresponding Source fixed durable physical medium customarily used software interchange. b) Convey object code , embodied , physical product (including physical distribution medium), accompanied written offer, valid least three years valid long offer spare parts customer support product model, give anyone possesses object code either (1) copy Corresponding Source software product covered License, durable physical medium customarily used software interchange, price reasonable cost physically performing conveying source, (2) access copy Corresponding Source network server charge. c) Convey individual copies object code copy written offer provide Corresponding Source. alternative allowed occasionally noncommercially, received object code offer, accord subsection 6b. d) Convey object code offering access designated place (gratis charge), offer equivalent access Corresponding Source way place charge. need require recipients copy Corresponding Source along object code. place copy object code network server, Corresponding Source may different server (operated third party) supports equivalent copying facilities, provided maintain clear directions next object code saying find Corresponding Source. Regardless server hosts Corresponding Source, remain obligated ensure available long needed satisfy requirements. e) Convey object code using peer--peer transmission, provided inform peers object code Corresponding Source work offered general public charge subsection 6d. separable portion object code, whose source code excluded Corresponding Source System Library, need included conveying object code work. “User Product” either (1) “consumer product”, means tangible personal property normally used personal, family, household purposes, (2) anything designed sold incorporation dwelling. determining whether product consumer product, doubtful cases shall resolved favor coverage. particular product received particular user, “normally used” refers typical common use class product, regardless status particular user way particular user actually uses, expects expected use, product. product consumer product regardless whether product substantial commercial, industrial non-consumer uses, unless uses represent significant mode use product. “Installation Information” User Product means methods, procedures, authorization keys, information required install execute modified versions covered work User Product modified version Corresponding Source. information must suffice ensure continued functioning modified object code case prevented interfered solely modification made. convey object code work section , , specifically use , User Product, conveying occurs part transaction right possession use User Product transferred recipient perpetuity fixed term (regardless transaction characterized), Corresponding Source conveyed section must accompanied Installation Information. requirement apply neither third party retains ability install modified object code User Product (example, work installed ROM). requirement provide Installation Information include requirement continue provide support service, warranty, updates work modified installed recipient, User Product modified installed. Access network may denied modification materially adversely affects operation network violates rules protocols communication across network. Corresponding Source conveyed, Installation Information provided, accord section must format publicly documented (implementation available public source code form), must require special password key unpacking, reading copying.","code":""},{"path":"https://avi-kenny.github.io/vaccine/LICENSE.html","id":"id_7-additional-terms","dir":"","previous_headings":"TERMS AND CONDITIONS","what":"7. Additional Terms","title":"GNU General Public License","text":"“Additional permissions” terms supplement terms License making exceptions one conditions. Additional permissions applicable entire Program shall treated though included License, extent valid applicable law. additional permissions apply part Program, part may used separately permissions, entire Program remains governed License without regard additional permissions. convey copy covered work, may option remove additional permissions copy, part . (Additional permissions may written require removal certain cases modify work.) may place additional permissions material, added covered work, can give appropriate copyright permission. Notwithstanding provision License, material add covered work, may (authorized copyright holders material) supplement terms License terms: ) Disclaiming warranty limiting liability differently terms sections 15 16 License; b) Requiring preservation specified reasonable legal notices author attributions material Appropriate Legal Notices displayed works containing ; c) Prohibiting misrepresentation origin material, requiring modified versions material marked reasonable ways different original version; d) Limiting use publicity purposes names licensors authors material; e) Declining grant rights trademark law use trade names, trademarks, service marks; f) Requiring indemnification licensors authors material anyone conveys material (modified versions ) contractual assumptions liability recipient, liability contractual assumptions directly impose licensors authors. non-permissive additional terms considered “restrictions” within meaning section 10. Program received , part , contains notice stating governed License along term restriction, may remove term. license document contains restriction permits relicensing conveying License, may add covered work material governed terms license document, provided restriction survive relicensing conveying. add terms covered work accord section, must place, relevant source files, statement additional terms apply files, notice indicating find applicable terms. Additional terms, permissive non-permissive, may stated form separately written license, stated exceptions; requirements apply either way.","code":""},{"path":"https://avi-kenny.github.io/vaccine/LICENSE.html","id":"id_8-termination","dir":"","previous_headings":"TERMS AND CONDITIONS","what":"8. Termination","title":"GNU General Public License","text":"may propagate modify covered work except expressly provided License. attempt otherwise propagate modify void, automatically terminate rights License (including patent licenses granted third paragraph section 11). However, cease violation License, license particular copyright holder reinstated () provisionally, unless copyright holder explicitly finally terminates license, (b) permanently, copyright holder fails notify violation reasonable means prior 60 days cessation. Moreover, license particular copyright holder reinstated permanently copyright holder notifies violation reasonable means, first time received notice violation License (work) copyright holder, cure violation prior 30 days receipt notice. Termination rights section terminate licenses parties received copies rights License. rights terminated permanently reinstated, qualify receive new licenses material section 10.","code":""},{"path":"https://avi-kenny.github.io/vaccine/LICENSE.html","id":"id_9-acceptance-not-required-for-having-copies","dir":"","previous_headings":"TERMS AND CONDITIONS","what":"9. Acceptance Not Required for Having Copies","title":"GNU General Public License","text":"required accept License order receive run copy Program. Ancillary propagation covered work occurring solely consequence using peer--peer transmission receive copy likewise require acceptance. However, nothing License grants permission propagate modify covered work. actions infringe copyright accept License. Therefore, modifying propagating covered work, indicate acceptance License .","code":""},{"path":"https://avi-kenny.github.io/vaccine/LICENSE.html","id":"id_10-automatic-licensing-of-downstream-recipients","dir":"","previous_headings":"TERMS AND CONDITIONS","what":"10. Automatic Licensing of Downstream Recipients","title":"GNU General Public License","text":"time convey covered work, recipient automatically receives license original licensors, run, modify propagate work, subject License. responsible enforcing compliance third parties License. “entity transaction” transaction transferring control organization, substantially assets one, subdividing organization, merging organizations. propagation covered work results entity transaction, party transaction receives copy work also receives whatever licenses work party’s predecessor interest give previous paragraph, plus right possession Corresponding Source work predecessor interest, predecessor can get reasonable efforts. may impose restrictions exercise rights granted affirmed License. example, may impose license fee, royalty, charge exercise rights granted License, may initiate litigation (including cross-claim counterclaim lawsuit) alleging patent claim infringed making, using, selling, offering sale, importing Program portion .","code":""},{"path":"https://avi-kenny.github.io/vaccine/LICENSE.html","id":"id_11-patents","dir":"","previous_headings":"TERMS AND CONDITIONS","what":"11. Patents","title":"GNU General Public License","text":"“contributor” copyright holder authorizes use License Program work Program based. work thus licensed called contributor’s “contributor version”. contributor’s “essential patent claims” patent claims owned controlled contributor, whether already acquired hereafter acquired, infringed manner, permitted License, making, using, selling contributor version, include claims infringed consequence modification contributor version. purposes definition, “control” includes right grant patent sublicenses manner consistent requirements License. contributor grants non-exclusive, worldwide, royalty-free patent license contributor’s essential patent claims, make, use, sell, offer sale, import otherwise run, modify propagate contents contributor version. following three paragraphs, “patent license” express agreement commitment, however denominated, enforce patent (express permission practice patent covenant sue patent infringement). “grant” patent license party means make agreement commitment enforce patent party. convey covered work, knowingly relying patent license, Corresponding Source work available anyone copy, free charge terms License, publicly available network server readily accessible means, must either (1) cause Corresponding Source available, (2) arrange deprive benefit patent license particular work, (3) arrange, manner consistent requirements License, extend patent license downstream recipients. “Knowingly relying” means actual knowledge , patent license, conveying covered work country, recipient’s use covered work country, infringe one identifiable patents country reason believe valid. , pursuant connection single transaction arrangement, convey, propagate procuring conveyance , covered work, grant patent license parties receiving covered work authorizing use, propagate, modify convey specific copy covered work, patent license grant automatically extended recipients covered work works based . patent license “discriminatory” include within scope coverage, prohibits exercise , conditioned non-exercise one rights specifically granted License. may convey covered work party arrangement third party business distributing software, make payment third party based extent activity conveying work, third party grants, parties receive covered work , discriminatory patent license () connection copies covered work conveyed (copies made copies), (b) primarily connection specific products compilations contain covered work, unless entered arrangement, patent license granted, prior 28 March 2007. Nothing License shall construed excluding limiting implied license defenses infringement may otherwise available applicable patent law.","code":""},{"path":"https://avi-kenny.github.io/vaccine/LICENSE.html","id":"id_12-no-surrender-of-others-freedom","dir":"","previous_headings":"TERMS AND CONDITIONS","what":"12. No Surrender of Others’ Freedom","title":"GNU General Public License","text":"conditions imposed (whether court order, agreement otherwise) contradict conditions License, excuse conditions License. convey covered work satisfy simultaneously obligations License pertinent obligations, consequence may convey . example, agree terms obligate collect royalty conveying convey Program, way satisfy terms License refrain entirely conveying Program.","code":""},{"path":"https://avi-kenny.github.io/vaccine/LICENSE.html","id":"id_13-use-with-the-gnu-affero-general-public-license","dir":"","previous_headings":"TERMS AND CONDITIONS","what":"13. Use with the GNU Affero General Public License","title":"GNU General Public License","text":"Notwithstanding provision License, permission link combine covered work work licensed version 3 GNU Affero General Public License single combined work, convey resulting work. terms License continue apply part covered work, special requirements GNU Affero General Public License, section 13, concerning interaction network apply combination .","code":""},{"path":"https://avi-kenny.github.io/vaccine/LICENSE.html","id":"id_14-revised-versions-of-this-license","dir":"","previous_headings":"TERMS AND CONDITIONS","what":"14. Revised Versions of this License","title":"GNU General Public License","text":"Free Software Foundation may publish revised /new versions GNU General Public License time time. new versions similar spirit present version, may differ detail address new problems concerns. version given distinguishing version number. Program specifies certain numbered version GNU General Public License “later version” applies , option following terms conditions either numbered version later version published Free Software Foundation. Program specify version number GNU General Public License, may choose version ever published Free Software Foundation. Program specifies proxy can decide future versions GNU General Public License can used, proxy’s public statement acceptance version permanently authorizes choose version Program. Later license versions may give additional different permissions. However, additional obligations imposed author copyright holder result choosing follow later version.","code":""},{"path":"https://avi-kenny.github.io/vaccine/LICENSE.html","id":"id_15-disclaimer-of-warranty","dir":"","previous_headings":"TERMS AND CONDITIONS","what":"15. Disclaimer of Warranty","title":"GNU General Public License","text":"WARRANTY PROGRAM, EXTENT PERMITTED APPLICABLE LAW. EXCEPT OTHERWISE STATED WRITING COPYRIGHT HOLDERS /PARTIES PROVIDE PROGRAM “” WITHOUT WARRANTY KIND, EITHER EXPRESSED IMPLIED, INCLUDING, LIMITED , IMPLIED WARRANTIES MERCHANTABILITY FITNESS PARTICULAR PURPOSE. ENTIRE RISK QUALITY PERFORMANCE PROGRAM . PROGRAM PROVE DEFECTIVE, ASSUME COST NECESSARY SERVICING, REPAIR CORRECTION.","code":""},{"path":"https://avi-kenny.github.io/vaccine/LICENSE.html","id":"id_16-limitation-of-liability","dir":"","previous_headings":"TERMS AND CONDITIONS","what":"16. Limitation of Liability","title":"GNU General Public License","text":"EVENT UNLESS REQUIRED APPLICABLE LAW AGREED WRITING COPYRIGHT HOLDER, PARTY MODIFIES /CONVEYS PROGRAM PERMITTED , LIABLE DAMAGES, INCLUDING GENERAL, SPECIAL, INCIDENTAL CONSEQUENTIAL DAMAGES ARISING USE INABILITY USE PROGRAM (INCLUDING LIMITED LOSS DATA DATA RENDERED INACCURATE LOSSES SUSTAINED THIRD PARTIES FAILURE PROGRAM OPERATE PROGRAMS), EVEN HOLDER PARTY ADVISED POSSIBILITY DAMAGES.","code":""},{"path":"https://avi-kenny.github.io/vaccine/LICENSE.html","id":"id_17-interpretation-of-sections-15-and-16","dir":"","previous_headings":"TERMS AND CONDITIONS","what":"17. Interpretation of Sections 15 and 16","title":"GNU General Public License","text":"disclaimer warranty limitation liability provided given local legal effect according terms, reviewing courts shall apply local law closely approximates absolute waiver civil liability connection Program, unless warranty assumption liability accompanies copy Program return fee. END TERMS CONDITIONS","code":""},{"path":"https://avi-kenny.github.io/vaccine/LICENSE.html","id":"how-to-apply-these-terms-to-your-new-programs","dir":"","previous_headings":"","what":"How to Apply These Terms to Your New Programs","title":"GNU General Public License","text":"develop new program, want greatest possible use public, best way achieve make free software everyone can redistribute change terms. , attach following notices program. safest attach start source file effectively state exclusion warranty; file least “copyright” line pointer full notice found. Also add information contact electronic paper mail. program terminal interaction, make output short notice like starts interactive mode: hypothetical commands show w show c show appropriate parts General Public License. course, program’s commands might different; GUI interface, use “box”. also get employer (work programmer) school, , sign “copyright disclaimer” program, necessary. information , apply follow GNU GPL, see <http://www.gnu.org/licenses/>. GNU General Public License permit incorporating program proprietary programs. program subroutine library, may consider useful permit linking proprietary applications library. want , use GNU Lesser General Public License instead License. first, please read <http://www.gnu.org/philosophy/--lgpl.html>.","code":"<one line to give the program's name and a brief idea of what it does.> Copyright (C) <year>  <name of author>  This program is free software: you can redistribute it and/or modify it under the terms of the GNU General Public License as published by the Free Software Foundation, either version 3 of the License, or (at your option) any later version.  This program is distributed in the hope that it will be useful, but WITHOUT ANY WARRANTY; without even the implied warranty of MERCHANTABILITY or FITNESS FOR A PARTICULAR PURPOSE.  See the GNU General Public License for more details.  You should have received a copy of the GNU General Public License along with this program.  If not, see <http://www.gnu.org/licenses/>. <program>  Copyright (C) <year>  <name of author> This program comes with ABSOLUTELY NO WARRANTY; for details type 'show w'. This is free software, and you are welcome to redistribute it under certain conditions; type 'show c' for details."},{"path":"https://avi-kenny.github.io/vaccine/authors.html","id":null,"dir":"","previous_headings":"","what":"Authors","title":"Authors and Citation","text":"Avi Kenny. Author, maintainer.","code":""},{"path":"https://avi-kenny.github.io/vaccine/authors.html","id":"citation","dir":"","previous_headings":"","what":"Citation","title":"Authors and Citation","text":"Kenny (2025). vaccine: Statistical Tools Immune Correlates Analysis Vaccine Clinical Trial Data. R package version 1.3.0, https://avi-kenny.github.io/vaccine/.","code":"@Manual{,   title = {vaccine: Statistical Tools for Immune Correlates Analysis of Vaccine Clinical Trial Data},   author = {Avi Kenny},   year = {2025},   note = {R package version 1.3.0},   url = {https://avi-kenny.github.io/vaccine/}, }"},{"path":"https://avi-kenny.github.io/vaccine/index.html","id":"vaccine-","dir":"","previous_headings":"","what":"Statistical Tools for Immune Correlates Analysis of Vaccine Clinical Trial Data","title":"Statistical Tools for Immune Correlates Analysis of Vaccine Clinical Trial Data","text":"Statistical tools immune correlates analysis vaccine clinical trial data","code":""},{"path":"https://avi-kenny.github.io/vaccine/index.html","id":"overview","dir":"","previous_headings":"","what":"Overview","title":"Statistical Tools for Immune Correlates Analysis of Vaccine Clinical Trial Data","text":"vaccine open-source R package containing various semiparametric nonparametric statistical tools immune correlates analysis vaccine clinical trial data. includes calculation summary statistics estimation risk, vaccine efficacy, controlled risk, controlled vaccine efficacy.","code":""},{"path":"https://avi-kenny.github.io/vaccine/index.html","id":"installation","dir":"","previous_headings":"","what":"Installation","title":"Statistical Tools for Immune Correlates Analysis of Vaccine Clinical Trial Data","text":"latest stable version vaccine can installed CRAN using install.packages(): current development version can installed using devtools::install_github():","code":"install.packages(\"vaccine\") devtools::install_github(repo=\"Avi-Kenny/vaccine\")"},{"path":"https://avi-kenny.github.io/vaccine/index.html","id":"documentation","dir":"","previous_headings":"","what":"Documentation","title":"Statistical Tools for Immune Correlates Analysis of Vaccine Clinical Trial Data","text":"full package documentation can found https://avi-kenny.github.io/vaccine/.","code":""},{"path":"https://avi-kenny.github.io/vaccine/index.html","id":"bugs-reports-and-feature-requests","dir":"","previous_headings":"","what":"Bugs reports and feature requests","title":"Statistical Tools for Immune Correlates Analysis of Vaccine Clinical Trial Data","text":"submit bug report request new feature, please submit new GitHub Issue.","code":""},{"path":"https://avi-kenny.github.io/vaccine/reference/as_table.html","id":null,"dir":"Reference","previous_headings":"","what":"Create table of estimates — as_table","title":"Create table of estimates — as_table","text":"Format estimates returned est_ce table","code":""},{"path":"https://avi-kenny.github.io/vaccine/reference/as_table.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Create table of estimates — as_table","text":"","code":"as_table(..., which = \"CR\", labels = NA)"},{"path":"https://avi-kenny.github.io/vaccine/reference/as_table.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Create table of estimates — as_table","text":"... One objects class \"vaccine_est\" returned est_ce. One c(\"CR\", \"CVE\"); controls whether table contains CR CVE values. labels character vector length equal length(list(...)) representing curve labels","code":""},{"path":"https://avi-kenny.github.io/vaccine/reference/as_table.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Create table of estimates — as_table","text":"table CR CVE values","code":""},{"path":"https://avi-kenny.github.io/vaccine/reference/as_table.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Create table of estimates — as_table","text":"","code":"data(hvtn505) dat <- load_data(time=\"HIVwk28preunblfu\", event=\"HIVwk28preunbl\", vacc=\"trt\",                  marker=\"IgG_V2\", covariates=c(\"age\",\"BMI\",\"bhvrisk\"),                  weights=\"wt\", ph2=\"casecontrol\", data=hvtn505) # \\donttest{ ests_cox <- est_ce(dat=dat, type=\"Cox\", t_0=578) ests_np <- est_ce(dat=dat, type=\"NP\", t_0=578) ests_table <- as_table(ests_cox, ests_np) head(ests_table) # }"},{"path":"https://avi-kenny.github.io/vaccine/reference/diagnostics.html","id":null,"dir":"Reference","previous_headings":"","what":"Run diagnostics — diagnostics","title":"Run diagnostics — diagnostics","text":"Run set diagnostic plots. Note function     work, est_ce must run return_extras=T.","code":""},{"path":"https://avi-kenny.github.io/vaccine/reference/diagnostics.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Run diagnostics — diagnostics","text":"","code":"diagnostics(obj)"},{"path":"https://avi-kenny.github.io/vaccine/reference/diagnostics.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Run diagnostics — diagnostics","text":"obj object class vaccine_est returned est_ce","code":""},{"path":"https://avi-kenny.github.io/vaccine/reference/diagnostics.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Run diagnostics — diagnostics","text":"combined plot model diagnostics","code":""},{"path":"https://avi-kenny.github.io/vaccine/reference/diagnostics.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Run diagnostics — diagnostics","text":"","code":"data(hvtn505) dat <- load_data(time=\"HIVwk28preunblfu\", event=\"HIVwk28preunbl\", vacc=\"trt\",                  marker=\"IgG_V2\", covariates=c(\"age\",\"BMI\",\"bhvrisk\"),                  weights=\"wt\", ph2=\"casecontrol\", data=hvtn505) # \\donttest{ ests_np <- est_ce(dat=dat, type=\"NP\", t_0=578, return_extras=TRUE) diagnostics(ests_np) # }"},{"path":"https://avi-kenny.github.io/vaccine/reference/est_ce.html","id":null,"dir":"Reference","previous_headings":"","what":"Estimate controlled effect curves — est_ce","title":"Estimate controlled effect curves — est_ce","text":"Estimate controlled risk (CR) curves /controlled vaccine     efficacy (CVE) curves. See references definitions curves.","code":""},{"path":"https://avi-kenny.github.io/vaccine/reference/est_ce.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Estimate controlled effect curves — est_ce","text":"","code":"est_ce(   dat,   type = \"Cox\",   t_0,   cr = TRUE,   cve = FALSE,   cr_placebo_arm = F,   s_out = seq(from = min(dat$s, na.rm = TRUE), to = max(dat$s, na.rm = TRUE), l = 101),   ci_type = \"transformed\",   placebo_risk_method = \"KM\",   return_p_value = FALSE,   return_extras = FALSE,   params_cox = params_ce_cox(),   params_np = params_ce_np() )"},{"path":"https://avi-kenny.github.io/vaccine/reference/est_ce.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Estimate controlled effect curves — est_ce","text":"dat data object returned load_data type One c(\"Cox\", \"NP\"). specifies whether estimate curve(s) using marginalized Cox proportional hazards model using monotone-constrained nonparametric estimator. t_0 Time point interest cr Boolean. TRUE, controlled risk (CR) curve computed returned. cve Boolean. TRUE, controlled vaccine efficacy (CVE) curve computed returned. cr_placebo_arm Boolean. TRUE, CR curve estimated placebo arm instead vaccine arm. s_out numeric vector s-values (biomarker scale) cve(s) /cr(s) computed. Defaults grid 101 points min max biomarker values. ci_type One c(\"transformed\", \"truncated\", \"regular\", \"none\"). ci_type=\"transformed\", confidence intervals computed logit(CR) /log(1-CVE) scale ensure confidence limits lie within [0,1] CR /lie within (-inf,1] CVE. ci_type=\"truncated\", confidence limits constructed CR /CVE scale truncated lie within [0,1] CR /lie within (-inf,1] CVE. ci_type=\"regular\", confidence limits transformed truncated. ci_type=\"none\", confidence intervals computed. placebo_risk_method One c(\"KM\", \"Cox\"). Method estimating overall risk placebo group. \"KM\" computes Kaplan-Meier estimate \"Cox\" computes estimate based marginalized Cox model survival curve. relevant cve=TRUE. return_p_value Boolean; TRUE, P-value corresponding null hypothesis CVE curve flat returned. type P-value corresponds type argument. return_extras Boolean; TRUE, objects useful debugging returned. params_cox list options returned params_ce_cox relevant type=\"Cox\". params_np list options returned params_ce_np relevant type=\"NP\".","code":""},{"path":"https://avi-kenny.github.io/vaccine/reference/est_ce.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Estimate controlled effect curves — est_ce","text":"list form list(cr=list(...), cve=list(...))     containing CR /CVE estimates. inner lists contains     following: s: vector marker values corresponding s_out est: vector point estimates ci_lower: vector confidence interval lower limits ci_upper: vector confidence interval upper limits","code":""},{"path":"https://avi-kenny.github.io/vaccine/reference/est_ce.html","id":"references","dir":"Reference","previous_headings":"","what":"References","title":"Estimate controlled effect curves — est_ce","text":"Gilbert P, Fong Y, Kenny , Carone, M (2022). Controlled     Effects Approach Assessing Immune Correlates Protection.     <doi:10.1093/biostatistics/kxac024>","code":""},{"path":"https://avi-kenny.github.io/vaccine/reference/est_ce.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Estimate controlled effect curves — est_ce","text":"","code":"data(hvtn505) dat <- load_data(time=\"HIVwk28preunblfu\", event=\"HIVwk28preunbl\", vacc=\"trt\",                  marker=\"IgG_V2\", covariates=c(\"age\",\"BMI\",\"bhvrisk\"),                  weights=\"wt\", ph2=\"casecontrol\", data=hvtn505) # \\donttest{ ests_cox <- est_ce(dat=dat, type=\"Cox\", t_0=578) ests_np <- est_ce(dat=dat, type=\"NP\", t_0=578) # }"},{"path":"https://avi-kenny.github.io/vaccine/reference/est_med.html","id":null,"dir":"Reference","previous_headings":"","what":"Estimate mediation effects — est_med","title":"Estimate mediation effects — est_med","text":"Estimate mediation effects, including natural direct effect     (NDE), natural indirect effect (NIE), proportion mediated     (PM). See references definitions objects.","code":""},{"path":"https://avi-kenny.github.io/vaccine/reference/est_med.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Estimate mediation effects — est_med","text":"","code":"est_med(   dat,   type = \"NP\",   t_0,   nde = TRUE,   nie = TRUE,   pm = TRUE,   scale = \"RR\",   params_np = params_med_np() )"},{"path":"https://avi-kenny.github.io/vaccine/reference/est_med.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Estimate mediation effects — est_med","text":"dat data object returned load_data type One c(\"NP\", \"Cox\"). specifies whether estimate effects using marginalized Cox proportional hazards model using nonparametric estimator. t_0 Time point interest nde Boolean. TRUE, natural direct effect computed returned. nie Boolean. TRUE, natural indirect effect computed returned. pm Boolean. TRUE, proportion mediated computed returned. scale One c(\"RR\", \"VE\"). determines whether NDE NIE estimates CIs computed risk ratio (RR) scale vaccine efficacy (VE) scale. latter equals one minus former. params_np list options returned params_med_np relevant type=\"NP\".","code":""},{"path":"https://avi-kenny.github.io/vaccine/reference/est_med.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Estimate mediation effects — est_med","text":"dataframe containing following columns: effect: one c(\"NDE\", \"NIE\", \"PM\") est: point estimate se: standard error point estimate ci_lower: confidence interval lower limit ci_upper: confidence interval upper limit","code":""},{"path":"https://avi-kenny.github.io/vaccine/reference/est_med.html","id":"references","dir":"Reference","previous_headings":"","what":"References","title":"Estimate mediation effects — est_med","text":"Fay MP Follmann DA (2023). Mediation Analyses Effect     Antibodies Vaccination <doi:10.48550/arXiv.2208.06465>","code":""},{"path":"https://avi-kenny.github.io/vaccine/reference/est_med.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Estimate mediation effects — est_med","text":"","code":"data(hvtn505) dat <- load_data(time=\"HIVwk28preunblfu\", event=\"HIVwk28preunbl\", vacc=\"trt\",                  marker=\"IgG_V2\", covariates=c(\"age\",\"BMI\",\"bhvrisk\"),                  weights=\"wt\", ph2=\"casecontrol\", data=hvtn505) # \\donttest{ ests_np <- est_med(dat=dat, type=\"NP\", t_0=578) # }"},{"path":"https://avi-kenny.github.io/vaccine/reference/est_overall.html","id":null,"dir":"Reference","previous_headings":"","what":"Estimate overall risk and vaccine efficacy — est_overall","title":"Estimate overall risk and vaccine efficacy — est_overall","text":"Estimate overall risk vaccine efficacy.","code":""},{"path":"https://avi-kenny.github.io/vaccine/reference/est_overall.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Estimate overall risk and vaccine efficacy — est_overall","text":"","code":"est_overall(dat, t_0, method = \"Cox\", risk = TRUE, ve = TRUE)"},{"path":"https://avi-kenny.github.io/vaccine/reference/est_overall.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Estimate overall risk and vaccine efficacy — est_overall","text":"dat data object returned load_data t_0 Time point interest method One c(\"KM\", \"Cox\"), corresponding either Kaplan-Meier estimator (\"KM\") marginalized Cox proportional hazards model (\"Cox\"). risk Boolean. TRUE, controlled risk (CR) curve computed. ve Boolean. TRUE, controlled vaccine efficacy (CVE) curve computed.","code":""},{"path":"https://avi-kenny.github.io/vaccine/reference/est_overall.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Estimate overall risk and vaccine efficacy — est_overall","text":"dataframe containing estimates","code":""},{"path":"https://avi-kenny.github.io/vaccine/reference/est_overall.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Estimate overall risk and vaccine efficacy — est_overall","text":"","code":"data(hvtn505) dat <- load_data(time=\"HIVwk28preunblfu\", event=\"HIVwk28preunbl\", vacc=\"trt\",                  marker=\"IgG_V2\", covariates=c(\"age\",\"BMI\",\"bhvrisk\"),                  weights=\"wt\", ph2=\"casecontrol\", data=hvtn505) est_overall(dat=dat, t_0=578, method=\"KM\")"},{"path":"https://avi-kenny.github.io/vaccine/reference/hvtn505.html","id":null,"dir":"Reference","previous_headings":"","what":"HVTN 505 Dataset — hvtn505","title":"HVTN 505 Dataset — hvtn505","text":"dataset HVTN 505 clinical trial","code":""},{"path":"https://avi-kenny.github.io/vaccine/reference/hvtn505.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"HVTN 505 Dataset — hvtn505","text":"","code":"data(hvtn505)"},{"path":"https://avi-kenny.github.io/vaccine/reference/hvtn505.html","id":"format","dir":"Reference","previous_headings":"","what":"Format","title":"HVTN 505 Dataset — hvtn505","text":"data frame 1,950 rows 10 variables: pub_id: Unique individual identifier trt: Treatment Assignment: 1=Vaccine, 0=Placebo HIVwk28preunbl: Indicator HIV-1 infection diagnosis /study       week 28 (day 196) prior Unblinding Date (Apr 22, 2013). HIVwk28preunblfu: Follow-time (days) HIV-1 infection       diagnosis endpoint Unblinding Date (22Apr2013) occuring       /study week 28 (day 196). age: Age (years) randomization BMI: Body Mass Index: (Weight Kg)/(Height meters)**2 bhvrisk: Baseline behavioral risk score casecontrol: Indicator inclusion case-control cohort wt: Inverse-probability--sampling weights, case-control       cohort IgG_env: IgG Binding gp120/140 IgG_V2: IgG Binding V1V2 IgG_V3: IgG Binding V3","code":""},{"path":"https://avi-kenny.github.io/vaccine/reference/hvtn505.html","id":"source","dir":"Reference","previous_headings":"","what":"Source","title":"HVTN 505 Dataset — hvtn505","text":"https://atlas.scharp.org/project/HVTN%20Public%20Data/HVTN%20505/begin.view","code":""},{"path":"https://avi-kenny.github.io/vaccine/reference/load_data.html","id":null,"dir":"Reference","previous_headings":"","what":"Load and format data object — load_data","title":"Load and format data object — load_data","text":"function takes user-supplied data returns data     object can read summary_stats,     est_ce, est_med, estimation     functions. Data expected come vaccine clinical trial,     possibly involving two-phase sampling possibly including biomarker     interest.","code":""},{"path":"https://avi-kenny.github.io/vaccine/reference/load_data.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Load and format data object — load_data","text":"","code":"load_data(   time,   event,   vacc,   marker,   covariates,   weights,   ph2,   strata = NA,   data,   covariates_ph2 = FALSE )"},{"path":"https://avi-kenny.github.io/vaccine/reference/load_data.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Load and format data object — load_data","text":"time character string; name numeric variable representing observed event censoring times. event character string; name binary variable corresponding whether observed time represents event time (1) censoring time (0). Either integer (0/1) Boolean (T/F) values allowed. vacc character string; name binary variable denoting whether individual vaccine group (1) placebo group (0). Accepts either integer (0/1) Boolean (T/F) values. marker character string; name numeric variable biomarker values. covariates character vector; names covariate columns. Columns values either numeric, binary, factors. Character columns converted factors. weights character string; name numeric variable containing inverse-probability--sampling (IPS) weights. ph2 character string; name binary variable representing whether individual phase-two cohort (1) (0). Accepts either integer (0/1) Boolean (T/F) values. strata character string; name variable containing strata identifiers (two-phase sampling strata). data dataframe containing vaccine trial data. covariates_ph2 boolean; least one covariates measured phase-two cohort, set TRUE.","code":""},{"path":"https://avi-kenny.github.io/vaccine/reference/load_data.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Load and format data object — load_data","text":"object class vaccine_dat.","code":""},{"path":"https://avi-kenny.github.io/vaccine/reference/load_data.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Load and format data object — load_data","text":"","code":"data(hvtn505) dat <- load_data(time=\"HIVwk28preunblfu\", event=\"HIVwk28preunbl\", vacc=\"trt\",                  marker=\"IgG_V2\", covariates=c(\"age\",\"BMI\",\"bhvrisk\"),                  weights=\"wt\", ph2=\"casecontrol\", data=hvtn505)"},{"path":"https://avi-kenny.github.io/vaccine/reference/params_ce_cox.html","id":null,"dir":"Reference","previous_headings":"","what":"Set parameters controlling Cox model estimation of controlled effect curves — params_ce_cox","title":"Set parameters controlling Cox model estimation of controlled effect curves — params_ce_cox","text":"used conjunction est_ce     set parameters controlling Cox model estimation controlled effect     curves; see examples.","code":""},{"path":"https://avi-kenny.github.io/vaccine/reference/params_ce_cox.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Set parameters controlling Cox model estimation of controlled effect curves — params_ce_cox","text":"","code":"params_ce_cox(spline_df = NA, spline_knots = NA, edge_ind = FALSE)"},{"path":"https://avi-kenny.github.io/vaccine/reference/params_ce_cox.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Set parameters controlling Cox model estimation of controlled effect curves — params_ce_cox","text":"spline_df integer; marker modeled flexibly within Cox model linear predictor natural cubic spline, option controls degrees freedom spline; knots chosen equally spaced across range marker. spline_knots numeric vector; alternative specifying spline_df, exact locations knots spline (including boundary knots) can specified option. edge_ind Boolean. TRUE, indicator variable corresponding lower limit marker included Cox model linear predictor.","code":""},{"path":"https://avi-kenny.github.io/vaccine/reference/params_ce_cox.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Set parameters controlling Cox model estimation of controlled effect curves — params_ce_cox","text":"list options.","code":""},{"path":"https://avi-kenny.github.io/vaccine/reference/params_ce_cox.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Set parameters controlling Cox model estimation of controlled effect curves — params_ce_cox","text":"","code":"data(hvtn505) dat <- load_data(time=\"HIVwk28preunblfu\", event=\"HIVwk28preunbl\", vacc=\"trt\",                  marker=\"IgG_V2\", covariates=c(\"age\",\"BMI\",\"bhvrisk\"),                  weights=\"wt\", ph2=\"casecontrol\", data=hvtn505) # \\donttest{ ests_cox <- est_ce(   dat = dat,   type = \"Cox\",   t_0 = 578,   params_cox = params_ce_cox(spline_df=4) ) # }"},{"path":"https://avi-kenny.github.io/vaccine/reference/params_ce_np.html","id":null,"dir":"Reference","previous_headings":"","what":"Set parameters controlling nonparametric estimation of controlled effect curves — params_ce_np","title":"Set parameters controlling nonparametric estimation of controlled effect curves — params_ce_np","text":"used conjunction est_ce     set parameters controlling nonparametric estimation controlled effect     curves; see examples.","code":""},{"path":"https://avi-kenny.github.io/vaccine/reference/params_ce_np.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Set parameters controlling nonparametric estimation of controlled effect curves — params_ce_np","text":"","code":"params_ce_np(   dir = \"decr\",   edge_corr = FALSE,   grid_size = list(y = 101, s = 101, x = 5),   surv_type = \"survML-G\",   density_type = \"binning\",   density_bins = 15,   deriv_type = \"m-spline\",   convex_type = \"GCM\" )"},{"path":"https://avi-kenny.github.io/vaccine/reference/params_ce_np.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Set parameters controlling nonparametric estimation of controlled effect curves — params_ce_np","text":"dir One c(\"decr\", \"incr\"); controls direction monotonicity. dir=\"decr\", assumed CR decreases function marker. dir=\"incr\", assumed CR increases function marker. edge_corr Boolean. TRUE, \"edge correction\" performed adjust bias near marker lower limit (see references). recommended edge correction performed least (roughly) 10 events corresponding marker lower limit. grid_size list keys y, s, x; controls rounding data values. Decreasing grid size values results shorter computation times, increasing values results precise estimates. grid_size$s=101, means grid 101 equally-spaced points (defining 100 intervals) created min(S) max(S), S value rounded nearest grid point. grid_size$y, grid created 0 t_0, extended max(Y). grid_size$x, separate grid created covariate column (binary/categorical covariates ignored). surv_type One c(\"Cox\", \"survSL\", \"survML-G\", \"survML-L\"); controls method use estimate conditional survival conditional censoring functions. type=\"Cox\", survival function based Cox proportional hazard model used. type=\"survSL\", Super Learner method Westling 2023 used. type=\"survML-G\", global survival stacking method Wolock 2022 used. type=\"survML-L\", local survival stacking method Polley 2011 used. density_type One c(\"binning\", \"parametric\"); controls method use estimate density ratio f(S|X)/f(S). density_bins integer; density_type=\"binning\", number bins use. density_bins=0, number bins selected via cross-validation. deriv_type One c(\"m-spline\", \"linear\"); controls method use estimate derivative CR curve. deriv_type=\"linear\", linear spline constructed based midpoints jump points estimated function (plus estimated function evaluated endpoints), numerically differentiated. deriv_type=\"m-spline\" similar deriv_type=\"linear\" smooths set points (using method Fritsch Carlson 1980) differentiating. convex_type One c(\"GCM\", \"CLS\"). Whether greatest convex minorant (\"GCM\") convex least squares (\"CLS\") projection used smoothing primitive estimator Gamma_n. convex_type=\"CLS\" experimental used caution.","code":""},{"path":"https://avi-kenny.github.io/vaccine/reference/params_ce_np.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Set parameters controlling nonparametric estimation of controlled effect curves — params_ce_np","text":"list options.","code":""},{"path":"https://avi-kenny.github.io/vaccine/reference/params_ce_np.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Set parameters controlling nonparametric estimation of controlled effect curves — params_ce_np","text":"","code":"data(hvtn505) dat <- load_data(time=\"HIVwk28preunblfu\", event=\"HIVwk28preunbl\", vacc=\"trt\",                  marker=\"IgG_V2\", covariates=c(\"age\",\"BMI\",\"bhvrisk\"),                  weights=\"wt\", ph2=\"casecontrol\", data=hvtn505) # \\donttest{ ests_np <- est_ce(   dat = dat,   type = \"NP\",   t_0 = 578,   params_np = params_ce_np(edge_corr=TRUE, surv_type=\"survML-L\") ) # }"},{"path":"https://avi-kenny.github.io/vaccine/reference/params_med_np.html","id":null,"dir":"Reference","previous_headings":"","what":"Set parameters controlling nonparametric estimation of mediation effects — params_med_np","title":"Set parameters controlling nonparametric estimation of mediation effects — params_med_np","text":"used conjunction est_med     set parameters controlling nonparametric estimation mediation effects;     see examples.","code":""},{"path":"https://avi-kenny.github.io/vaccine/reference/params_med_np.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Set parameters controlling nonparametric estimation of mediation effects — params_med_np","text":"","code":"params_med_np(   grid_size = list(y = 101, s = 101, x = 5),   surv_type = \"survML-G\",   density_type = \"binning\",   density_bins = 15 )"},{"path":"https://avi-kenny.github.io/vaccine/reference/params_med_np.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Set parameters controlling nonparametric estimation of mediation effects — params_med_np","text":"grid_size list keys y, s, x; controls rounding data values. Decreasing grid size values results shorter computation times, increasing values results precise estimates. grid_size$s=101, means grid 101 equally-spaced points (defining 100 intervals) created min(S) max(S), S value rounded nearest grid point. grid_size$y, grid created 0 t_0, extended max(Y). grid_size$x, separate grid created covariate column (binary/categorical covariates ignored). surv_type One c(\"Cox\", \"survSL\", \"survML-G\", \"survML-L\"); controls method use estimate conditional survival conditional censoring functions. type=\"Cox\", survival function based Cox proportional hazard model used. type=\"survSL\", Super Learner method Westling 2023 used. type=\"survML-G\", global survival stacking method Wolock 2022 used. type=\"survML-L\", local survival stacking method Polley 2011 used. density_type One c(\"binning\", \"parametric\"); controls method use estimate density ratio f(S|X)/f(S). density_bins integer; density_type=\"binning\", number bins use. density_bins=0, number bins selected via cross-validation.","code":""},{"path":"https://avi-kenny.github.io/vaccine/reference/params_med_np.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Set parameters controlling nonparametric estimation of mediation effects — params_med_np","text":"list options.","code":""},{"path":"https://avi-kenny.github.io/vaccine/reference/params_med_np.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Set parameters controlling nonparametric estimation of mediation effects — params_med_np","text":"","code":"data(hvtn505) dat <- load_data(time=\"HIVwk28preunblfu\", event=\"HIVwk28preunbl\", vacc=\"trt\",                  marker=\"IgG_V2\", covariates=c(\"age\",\"BMI\",\"bhvrisk\"),                  weights=\"wt\", ph2=\"casecontrol\", data=hvtn505) # \\donttest{ ests_med <- est_med(   dat = dat,   type = \"NP\",   t_0 = 578,   params_np = params_med_np(surv_type=\"survML-L\") ) # }"},{"path":"https://avi-kenny.github.io/vaccine/reference/plot_ce.html","id":null,"dir":"Reference","previous_headings":"","what":"Plotting controlled effect curves — plot_ce","title":"Plotting controlled effect curves — plot_ce","text":"Plot CR /CVE curves","code":""},{"path":"https://avi-kenny.github.io/vaccine/reference/plot_ce.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Plotting controlled effect curves — plot_ce","text":"","code":"plot_ce(   ...,   which = \"CR\",   density_type = \"none\",   dat = NA,   dat_alt = NA,   zoom_x = \"zoom in\",   zoom_y = \"zoom out\",   labels = NA,   bw = \"ucv\",   adjust = 1 )"},{"path":"https://avi-kenny.github.io/vaccine/reference/plot_ce.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Plotting controlled effect curves — plot_ce","text":"... One objects class \"vaccine_est\" returned est_ce. One c(\"CR\", \"CVE\"); controls whether plot CR curves CVE curves. density_type One c(\"none\", \"kde\", \"kde edge\"). Controls type estimator used background marker density plot. \"none\", density plot displayed. \"kde\", weighted kernel density estimator used. \"kde edge\", modified version \"kde\" used allows possible point mass left edge marker distribution. dat data object originally passed est_ce, used plotting densities. necessary pass density_type set \"none\". dat_alt Alternative data object; list containing one dataframes, form data.frame(s=..., weights=...). Column s contains biomarker values column weights contains corresponding two-phase sampling weights. can used alternative specifying dat, particularly useful plotting multiple densities single plot. plotting multiple densities, order dataframes correspond order \"vaccine_est\" objects passed . See examples. zoom_x Either one c(\"zoom \", \"zoom \") vector length 2. Controls zooming X-axis. default \"zoom \" set zoom limits plot estimates. Choosing \"zoom \" set zoom limits show entire distribution marker. Entering vector length 2 set left right zoom limits explicitly. zoom_y Either \"zoom \" vector length 2. Controls zooming Y-axis. default \"zoom \" show entire vertical range estimates. Entering vector length 2 set lower upper zoom limits explicitly. labels character vector length equal length list(...), representing plot labels. used length(list(...))>1. bw Bandwidth type kernel density; passed stats::density adjust Bandwidth adjustment factor kernel density; passed stats::density","code":""},{"path":"https://avi-kenny.github.io/vaccine/reference/plot_ce.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Plotting controlled effect curves — plot_ce","text":"plot CR/CVE estimates","code":""},{"path":"https://avi-kenny.github.io/vaccine/reference/plot_ce.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Plotting controlled effect curves — plot_ce","text":"","code":"# \\donttest{ # Plot one curve data(hvtn505) dat <- load_data(time=\"HIVwk28preunblfu\", event=\"HIVwk28preunbl\", vacc=\"trt\",                  marker=\"IgG_V2\", covariates=c(\"age\",\"BMI\",\"bhvrisk\"),                  weights=\"wt\", ph2=\"casecontrol\", data=hvtn505) ests_cox <- est_ce(dat=dat, type=\"Cox\", t_0=578) plot_ce(ests_cox, density_type=\"kde\", dat=dat)  # Trim display of plot according to quantiles of the biomarker distribution ests_cox_tr <- trim(ests_cox, dat=dat, quantiles=c(0.05,0.95)) plot_ce(ests_cox_tr, density_type=\"kde\", dat=dat)  # Plot multiple curves (same biomarker) ests_np <- est_ce(dat=dat, type=\"NP\", t_0=578) plot_ce(ests_cox, ests_np, density_type=\"kde\", dat=dat)  # Plot multiple curves (two different biomarkers) dat2 <- load_data(time=\"HIVwk28preunblfu\", event=\"HIVwk28preunbl\", vacc=\"trt\",                   marker=\"IgG_env\", covariates=c(\"age\",\"BMI\",\"bhvrisk\"),                   weights=\"wt\", ph2=\"casecontrol\", data=hvtn505) ests_cox2 <- est_ce(dat=dat2, type=\"Cox\", t_0=578) dat_alt <- list(   data.frame(s=dat$s[dat$a==1], weights=dat$weights[dat$a==1]),   data.frame(s=dat2$s[dat2$a==1], weights=dat2$weights[dat2$a==1]) ) plot_ce(ests_cox, ests_cox2, density_type=\"kde\", dat_alt=dat_alt) # }"},{"path":[]},{"path":"https://avi-kenny.github.io/vaccine/reference/summary_stats.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Calculate summary statistics — summary_stats","text":"","code":"summary_stats(dat, quietly = FALSE)"},{"path":"https://avi-kenny.github.io/vaccine/reference/summary_stats.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Calculate summary statistics — summary_stats","text":"dat data object returned `load_data`. quietly Boolean. true, output printed.","code":""},{"path":"https://avi-kenny.github.io/vaccine/reference/summary_stats.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Calculate summary statistics — summary_stats","text":"list containing values various summary statistics.","code":""},{"path":"https://avi-kenny.github.io/vaccine/reference/summary_stats.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Calculate summary statistics — summary_stats","text":"","code":"data(hvtn505) dat <- load_data(time=\"HIVwk28preunblfu\", event=\"HIVwk28preunbl\", vacc=\"trt\",                  marker=\"IgG_V2\", covariates=c(\"age\",\"BMI\",\"bhvrisk\"),                  weights=\"wt\", ph2=\"casecontrol\", data=hvtn505) summary_stats(dat=dat)"},{"path":"https://avi-kenny.github.io/vaccine/reference/trim.html","id":null,"dir":"Reference","previous_headings":"","what":"Trim data for plotting/reporting — trim","title":"Trim data for plotting/reporting — trim","text":"Removes subset estimates returned est_ce","code":""},{"path":"https://avi-kenny.github.io/vaccine/reference/trim.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Trim data for plotting/reporting — trim","text":"","code":"trim(ests, dat, quantiles, placebo = FALSE)"},{"path":"https://avi-kenny.github.io/vaccine/reference/trim.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Trim data for plotting/reporting — trim","text":"ests object class \"vaccine_est\" returned est_ce. dat data object originally passed est_ce. quantiles vector length 2 representing quantiles marker distribution trim data; , example, quantiles=c(0.1,0.9) specified, values outside 10 (weighted) quantiles marker distribution trimmed. placebo Boolean; TRUE, quantiles computed based marker distribution placebo arm instead vaccine arm","code":""},{"path":"https://avi-kenny.github.io/vaccine/reference/trim.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Trim data for plotting/reporting — trim","text":"modified copy ests data trimmed.","code":""},{"path":"https://avi-kenny.github.io/vaccine/reference/trim.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Trim data for plotting/reporting — trim","text":"","code":"# \\donttest{ data(hvtn505) dat <- load_data(time=\"HIVwk28preunblfu\", event=\"HIVwk28preunbl\", vacc=\"trt\",                  marker=\"IgG_V2\", covariates=c(\"age\",\"BMI\",\"bhvrisk\"),                  weights=\"wt\", ph2=\"casecontrol\", data=hvtn505) ests_cox <- est_ce(dat=dat, type=\"Cox\", t_0=578) ests_cox_tr <- trim(ests_cox, dat=dat, quantiles=c(0.05,0.95)) plot_ce(ests_cox_tr, density_type=\"kde\", dat=dat) # }"},{"path":"https://avi-kenny.github.io/vaccine/reference/vaccine-package.html","id":null,"dir":"Reference","previous_headings":"","what":"vaccine: Statistical Tools for Immune Correlates Analysis of Vaccine Clinical Trial Data — vaccine-package","title":"vaccine: Statistical Tools for Immune Correlates Analysis of Vaccine Clinical Trial Data — vaccine-package","text":"Various semiparametric nonparametric statistical tools immune correlates analysis vaccine clinical trial data. includes calculation summary statistics estimation risk, vaccine efficacy, controlled effects (controlled risk controlled vaccine efficacy), mediation effects (natural direct effect, natural indirect effect, proportion mediated). See Gilbert P, Fong Y, Kenny , Carone, M (2022) doi:10.1093/biostatistics/kxac024  Fay MP Follmann DA (2023) doi:10.48550/arXiv.2208.06465 .","code":""},{"path":[]},{"path":"https://avi-kenny.github.io/vaccine/reference/vaccine-package.html","id":"author","dir":"Reference","previous_headings":"","what":"Author","title":"vaccine: Statistical Tools for Immune Correlates Analysis of Vaccine Clinical Trial Data — vaccine-package","text":"Maintainer: Avi Kenny avi.kenny@gmail.com","code":""},{"path":"https://avi-kenny.github.io/vaccine/news/index.html","id":"vaccine-130","dir":"Changelog","previous_headings":"","what":"vaccine 1.3.0","title":"vaccine 1.3.0","text":"CRAN release: 2025-01-07","code":""},{"path":"https://avi-kenny.github.io/vaccine/news/index.html","id":"major-changes-1-3-0","dir":"Changelog","previous_headings":"","what":"Major changes","title":"vaccine 1.3.0","text":"Allow controlled risk (CR) curves estimated placebo arm Added ability plot multiple density plots single graph via plot() function","code":""},{"path":"https://avi-kenny.github.io/vaccine/news/index.html","id":"minor-changes-1-3-0","dir":"Changelog","previous_headings":"","what":"Minor changes","title":"vaccine 1.3.0","text":"Updated trim() function work placebo arm data Removed dependency simest package Updated package logo Fixed bug nonparametric CVE P-values Fixed bug associated reading datasets categorical covariates Downgraded ranger required version 0.16.0 0.14.0","code":""},{"path":"https://avi-kenny.github.io/vaccine/news/index.html","id":"vaccine-121","dir":"Changelog","previous_headings":"","what":"vaccine 1.2.1","title":"vaccine 1.2.1","text":"CRAN release: 2024-02-16","code":""},{"path":"https://avi-kenny.github.io/vaccine/news/index.html","id":"minor-changes-1-2-1","dir":"Changelog","previous_headings":"","what":"Minor changes","title":"vaccine 1.2.1","text":"Fixed bug displayed incorrect package version number startup. Tweaked SuperLearner library involved standard error estimation est_ce(..., type=\"NP\"), resulting improved performance. Fixed bug related plot_ce(..., density_type=\"kde edge\"). Fixed minor bug related SuperLearner package introduced version 1.2.0.","code":""},{"path":"https://avi-kenny.github.io/vaccine/news/index.html","id":"vaccine-120","dir":"Changelog","previous_headings":"","what":"vaccine 1.2.0","title":"vaccine 1.2.0","text":"CRAN release: 2024-02-14","code":""},{"path":"https://avi-kenny.github.io/vaccine/news/index.html","id":"major-changes-1-2-0","dir":"Changelog","previous_headings":"","what":"Major changes","title":"vaccine 1.2.0","text":"Added trim function, can used conjunction plot_ce function truncate display estimate objects produced est_ce. Specifically, estimates X-coordinates lie outside specified quantiles observed distribution marker removed. See package vignette examples. Added as_table function, formats estimate objects produced using est_ce table.","code":""},{"path":"https://avi-kenny.github.io/vaccine/news/index.html","id":"minor-changes-1-2-0","dir":"Changelog","previous_headings":"","what":"Minor changes","title":"vaccine 1.2.0","text":"Implemented various changes plot_ce function: added background kernel density plotting, changed default plot styling, fixed bug caused CR plots displayed instead CVE plots plot_ce(..., =\"CVE\") called, added plotting section main package vignette.","code":""},{"path":"https://avi-kenny.github.io/vaccine/news/index.html","id":"vaccine-110","dir":"Changelog","previous_headings":"","what":"vaccine 1.1.0","title":"vaccine 1.1.0","text":"CRAN release: 2023-12-04","code":""},{"path":"https://avi-kenny.github.io/vaccine/news/index.html","id":"major-changes-1-1-0","dir":"Changelog","previous_headings":"","what":"Major changes","title":"vaccine 1.1.0","text":"est_ce, added option return_p_value; set TRUE, P-value returned corresponding null hypothesis CVE curve (equivalently, CR curve vaccine group) constant. type='Cox' specified, Wald-type test using estimated Cox model parameter vector. type='NP', nonparametric test assuming monotonicity curve.","code":""},{"path":"https://avi-kenny.github.io/vaccine/news/index.html","id":"minor-changes-1-1-0","dir":"Changelog","previous_headings":"","what":"Minor changes","title":"vaccine 1.1.0","text":"Fixed importing factor/character variables load_data.","code":""},{"path":"https://avi-kenny.github.io/vaccine/news/index.html","id":"vaccine-100","dir":"Changelog","previous_headings":"","what":"vaccine 1.0.0","title":"vaccine 1.0.0","text":"CRAN release: 2023-10-20","code":""},{"path":"https://avi-kenny.github.io/vaccine/news/index.html","id":"major-changes-1-0-0","dir":"Changelog","previous_headings":"","what":"Major changes","title":"vaccine 1.0.0","text":"Added functions nonparametric estimation inference mediation analysis parameters, including natural direct effect, natural indirect effect, proportion mediated. Adapted nonparametric Cox-based CVE estimation inference handle settings covariates measured phase two (e.g., applicable settings researchers want control baseline biomarker measurement). Added confidence band monotonization nonparametric CVE inference.","code":""},{"path":"https://avi-kenny.github.io/vaccine/news/index.html","id":"minor-changes-1-0-0","dir":"Changelog","previous_headings":"","what":"Minor changes","title":"vaccine 1.0.0","text":"Various minor bug fixes code speed improvements. Completed unit testing framework increased code coverage 67%.","code":""},{"path":"https://avi-kenny.github.io/vaccine/news/index.html","id":"vaccine-010","dir":"Changelog","previous_headings":"","what":"vaccine 0.1.0","title":"vaccine 0.1.0","text":"CRAN release: 2023-07-08","code":""},{"path":"https://avi-kenny.github.io/vaccine/news/index.html","id":"major-changes-0-1-0","dir":"Changelog","previous_headings":"","what":"Major changes","title":"vaccine 0.1.0","text":"Initial package release","code":""},{"path":"https://avi-kenny.github.io/vaccine/news/index.html","id":"minor-changes-0-1-0","dir":"Changelog","previous_headings":"","what":"Minor changes","title":"vaccine 0.1.0","text":"None","code":""}]
